Publications
BMT CTN investigators have published >135 manuscripts, including >30 primary study results papers, in numerous peer-reviewed journals, including the New England Journal of Medicine, Journal of Clinical Oncology, and Blood. Selected publications are summarized for dissemination to patients and the lay public.
Note: Some Publications were unable to be listed below - please see that listing here. All other publications based on PubMedIDs are listed below.
Found 25 results
Filters: Author is Logan, Brent R [Clear All Filters]
,
“Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year.”, Transplant Cell Ther, vol. 27, no. 11, pp. 885-907, 2021.
, “Impact of Changes of the 2020 Consensus Definitions of Invasive Aspergillosis on Clinical Trial Design: Unintended Consequences for Prevention Trials?”, Open Forum Infect Dis, vol. 8, no. 10, p. ofab441, 2021.
, “Impact of Conditioning Intensity and Genomics on Relapse After Allogeneic Transplantation for Patients With Myelodysplastic Syndrome.”, JCO Precis Oncol, vol. 5, 2021.
, “A unified approach to sample size and power determination for testing parameters in generalized linear and time-to-event regression models.”, Stat Med, vol. 40, no. 5, pp. 1121-1132, 2021.
, “Group sequential tests for treatment effect on survival and cumulative incidence at a fixed time point.”, Lifetime Data Anal, vol. 26, no. 3, pp. 603-623, 2020.
, “Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease.”, J Clin Oncol, vol. 38, no. 12, pp. 1273-1283, 2020.
, “Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial.”, Blood, vol. 135, no. 2, pp. 97-107, 2020.
, “Kinetics of immune cell reconstitution predict survival in allogeneic bone marrow and G-CSF-mobilized stem cell transplantation.”, Blood Adv, vol. 3, no. 15, pp. 2250-2263, 2019.
, “Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with ”, Lancet Haematol, vol. 6, no. 3, pp. e132-e143, 2019.
, “A group sequential test for treatment effect based on the Fine-Gray model.”, Biometrics, vol. 74, no. 3, pp. 1006-1013, 2018.
, “A phase II/III randomized, multicenter trial of prednisone/sirolimus prednisone/ sirolimus/calcineurin inhibitor for the treatment of chronic graft--host disease: BMT CTN 0801.”, Haematologica, vol. 103, no. 11, pp. 1915-1924, 2018.
, “Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.”, J Clin Oncol, vol. 35, no. 11, pp. 1154-1161, 2017.
, “Plasma biomarkers of risk for death in a multicenter phase 3 trial with uniform transplant characteristics post-allogeneic HCT.”, Blood, vol. 129, no. 2, pp. 162-170, 2017.
, “Infections after Transplantation of Bone Marrow or Peripheral Blood Stem Cells from Unrelated Donors.”, Biol Blood Marrow Transplant, vol. 22, no. 2, pp. 359-370, 2016.
, “Patient-Reported Outcomes and Socioeconomic Status as Predictors of Clinical Outcomes after Hematopoietic Stem Cell Transplantation: A Study from the Blood and Marrow Transplant Clinical Trials Network 0902 Trial.”, Biol Blood Marrow Transplant, vol. 22, no. 12, pp. 2256-2263, 2016.
, “Recovery of Unrelated Donors of Peripheral Blood Stem Cells versus Recovery of Unrelated Donors of Bone Marrow: A Prespecified Analysis from the Phase III Blood and Marrow Transplant Clinical Trials Network Protocol 0201.”, Biol Blood Marrow Transplant, vol. 22, no. 6, pp. 1108-1116, 2016.
, “A trial of unrelated donor marrow transplantation for children with severe sickle cell disease.”, Blood, vol. 128, no. 21, pp. 2561-2567, 2016.
, “Improved survival after transplantation of more donor plasmacytoid dendritic or naïve T cells from unrelated-donor marrow grafts: results from BMTCTN 0201.”, J Clin Oncol, vol. 32, no. 22, pp. 2365-72, 2014.
, “Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802.”, Blood, vol. 124, no. 22, pp. 3221-7; quiz 3335, 2014.
, “Randomized, double-blind, placebo-controlled trial of soluble tumor necrosis factor receptor: enbrel (etanercept) for the treatment of idiopathic pneumonia syndrome after allogeneic stem cell transplantation: blood and marrow transplant clinical trials ne”, Biol Blood Marrow Transplant, vol. 20, no. 6, pp. 858-64, 2014.
, “Lymphocyte phenotype during therapy for acute graft-versus-host disease: a brief report from BMT-CTN 0302.”, Biol Blood Marrow Transplant, vol. 19, no. 3, pp. 481-5, 2013.
, “The use of group sequential designs with common competing risks tests.”, Stat Med, vol. 32, no. 6, pp. 899-913, 2013.
, “Peripheral-blood stem cells versus bone marrow from unrelated donors.”, N Engl J Med, vol. 367, no. 16, pp. 1487-96, 2012.
,